Portage Biotech

121 articles about Portage Biotech

• Portage Granted Extension by CSE to Cure Default; Comments on OTC Trading and Provides Audit Update

  11/27/2019

  Company was also deemed to be in default under the rules of the CSE which resulted in the suspension of trading in the Company's shares.

• Portage provides default status report - Oct. 31, 2019

  10/31/2019

  Portage Biotech Inc. is providing the following update on the status of efforts being made to revoke a failure to file cease trade order issued by the Ontario Securities Commission on August 2, 2019 against the securities of the Company.

• Portage Provides Default Status Report

  8/26/2019

  Portage Biotech Inc. (PBT.U, OTC Markets: PTGEF) ("Portage" or the "Company") is providing an update on the status of the filing of its audited annual financial statements for the year ended March 31, 2019, accompanying management discussion and analysis together with the related certifications (collectively, the "Annual Filings").

• Portage Confirms Delay in Annual Filings; Expects Issuance of Cease Trade Order

  7/31/2019

  Portage Biotech Inc. announced that, further to its news release of July 26, 2019, it will be delayed in filing its audited annual financial statements for the year ended March 31, 2019, the related management's discussion and analysis and certificates of its CEO and CFO with Canadian securities regulators until after deadline.

• Portage Announces Filing of Application for Management Cease Trade Order

  7/26/2019

  Portage Biotech Inc., announced that it will likely miss its filing deadline of July 29, 2019 to file its annual financial statements for the fiscal year ended March 31, 2019 and related management discussion and analysis as required by applicable Canadian securities laws.

• Portage Announces Increase in Holdings of Portfolio Company, Intensity Therapeutics With Positive Business, Regulatory, & Clinical Updates

  7/11/2019

  Portage Biotech Inc., ("Portage" or the "Company") (CSE: PBT.U, OTC Markets: PTGEF) today announced it has entered in an agreement with Fast Forward Innovations Limited (AIM Market: FFWD) ("Fast Forward") to purchase Intensity Holdings Limited ("IHL"), a wholly-owned subsidiary of fast forward.

• Portage Announces Change of CEO

  5/6/2019

  The Board of Directors of Portage Biotech Inc announces that Dr. Declan Doogan, the current Chief Executive Officer ("CEO") has decided to step down with immediate effect.

• Portage makes additional investment in Stimunity S.A, a Paris-based cancer immunotherapy company.

  3/25/2019

  Portage Biotech Inc., is pleased to announce that it has made an additional €600k investment in its associate, Stimunity, the Paris-based cancer immunotherapy company focused on STING.

• Portage Announces Change of Auditors

  3/12/2019

  Portage Biotech Inc. announces that it has changed its auditors from Swartz Lewisky Feldman LLP to Marcum LLP effective immediately.

• Portage Biotech Inc. - CSE to Issue Final Bulletin Regarding SalvaRx Acquisition

  2/8/2019

  Portage Biotech Inc. wishes to announce that due to an oversight, closing of the SalvaRx Acquisition was completed prior to obtaining final CSE approval.

• Portage provides updates on trading of its shares on OTC Markets

  1/30/2019

  FINRA also imposed trading halt on our shares on OTC Market.

• Portage Provides Additional Information Relating to the Independent Director Review of the Proposed Acquisition of SalvaRx Limited

  12/19/2018

  The purpose of this press release is to provide supplemental disclosure to the Corporation's management information circular and proxy statement dated November 26, 2018 in respect of the Annual and Special Meeting of the Shareholders of the Corporation to be held at 10:00 am (Toronto time) on January 8, 2019.

• Further subscription of US$950,00 in Convertible Loan Notes to iOx Therapeutics

  12/10/2018

  iOx Therapeutics is a United Kingdom-based immuno-oncology company.

• Portage posts meeting materials; trading on CSE expected to resume shortly; overview of combined Portage/SalvaRx portfolio

  11/27/2018

  Further to its news release of November 21, 2018, Portage Biotech Inc. is very pleased to announce that it has published and posted its shareholder meeting materials which provide information regarding the rationale and key business terms for the proposed acquisition of SalvaRx Limited ("SalvaRx") from SalvaRx Group plc

• Portage announces setting of meeting date to approve SalvaRx acquisition

  11/21/2018

  The meeting is scheduled for January 8th, 2019 for shareholders of record as of November 23, 2018.

• Portage provides update on SalvaRx portfolio company, Intensity Therapeutics, Inc.

  10/22/2018

  Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a SalvaRx Limited portfolio company, Intensity Therapeutics, Inc. ("Intensity"). SalvaRx Limited holds an 8.5% equity interest in Intensity.

• Portage Provides update on proposed acquisition of SalvaRx

  8/28/2018

  Portage Biotech Inc. ("Portage" or the "Company") wishes to announce that, further to its news release of August 14, 2018 announcing the proposed acquisition of SalvaRx Limited from SalvaRx Group plc, it has now submitted draft shareholder meeting materials to CSE for review.

• Portage provides update on its associate, Stimunity S.A, a Paris-based cancer immunotherapy company

  6/4/2018

  Portage Biotech Inc. is pleased to announce that the US Patent Office has granted Stimunity its main patent, US2016/074507, entitled "Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response."

• Portage invests in iOx Therapeutics, an United Kingdom-based cancer immunotherapy company

  3/8/2018

  Portage will invest US$950,000 by subscribing to an unsecured, one-year convertible loan instrument.

• Portage invests in Stimunity S.A, a Paris-based cancer immunotherapy company

  2/28/2018

  Stimunity will use the proceeds of this seed round to fund the preclinical development of its lead product, a potent biologic enhancer of the STING pathway that activates the immune system against tumor cells.